PHILIP MITCHELL AND BRENT WATERS
Psychiatry has long recognised the significant role of genetic factors in the development of the so-called 'functional psychoses'. In the nineteenth century the influential French psychiatrist Morel' viewed hereditary weakness as the major causal contributor to these disorders. At the turn of this century Kraeplin' recognised the constitutional or inherited basis of conditions, such as 'periodic insanity', which included manic, circular and depressive forms. Formal scientific research began in the 1930s with the pioneering twin studies of Kallmann.' Despite many subsequent studies of both schizophrenia and bipolar disorder, however, both the mode of inheritance and the nature of the abnormalities transmitted have eluded definition.
It is, therefore, of some significance that two recent studies have reported the localisation of dominant genes that appear to confer a strong predisposition to bipolar disorder. The first paper published was that of Egeland et ~l . ,~ who located a dominant gene on chromosome 1 1. The second study, by Mendlewicz et al.,' found a locus on the X-chromosome. These are the first studies to demonstrate linkage of particular regions of the genome to one of the functional psychoses.
Few psychiatrists will be familiar with molecular biology (and i n particular recombinant-DNA technology), the newly developed scientific field that provided the tools for these important discoveries. In fact, the full implications of molecular biology for internal medicine itself are only now being recogni~ed.~.' Current uses of this technology vary from the study of cancer-producing 'oncogenes' to the production of hormones, such as insulin, by genetic engineering.
The studies of Egeland and Mendlewicz used molecular biology as a sophisticated tool in the time-honoured genetic technique of linkage analysis. The basic principle underlying linkage analysis is that genes located close to each other in the parent are more likely to be inherited together by the offspring. They do not undergo recombination, the process that normally produces the reassortment of genes during Previous use of linkage analysis in psychiatry has included unsuccessful attempts to link bipolar illness to colour-blindness (an X-chromosome disorder)" and to HLA antigens.12 Molecular biology allows for the potential linkage to specific regions of the genome, even where no biochemical abnormality is known a priori. This technique is initially easier to use if there is evidence for a single responsible gene, or at least one major locus. It is, however, also suitable for multifactorial disorders, as demonstrated in recent studies of cardiovascular disease.
Within the last few years linkage analysis has been used to locate the vicinity of the genes responsible for many condition^,'^ including Huntington's chorea (chromosome 4)14 and familial Alzheimer's disease (chromosome 2 l)?
The more complicated step of determining the precise site of the abnormal gene has only been completed for Duchenne's muscular dystrophy (X-chromosome)16 a n d retinoblastoma (chromosome 13)'' As yet the protein products of these genes have not been characterised.
The major tools of molecular biology are restriction enzymes (endonucleases) and probes.18 DNA is extracted from the white cells of peripheral blood samples and is 'digested' by one of at least 150 restriction enzymes. These enzymes each recognise a specific sequence of the nucleotide bases that make up the DNA, dividing the DNA at each point where that particular sequence occurs. This process results in the production of multiple small fragments of DNA, which are then separated by size by electrophoresis a n d transferred t o a nitrocellulose filter.
The 'probes' are fragments of DNA (purified by 'cloning') that are complementary to particular regions of DNA in the genome. Currently, there are several hundred probes that can act as markers for known regions of the 23 human chromosomes. To test for linkage of a disorder to a particular region of the genome (or, less frequently, to a particular known gene), a DNA probe specific for that region is chosen and labelled, for example, with a radioisotope.
The nitrocellulose filter with the separated DNA fragments is then exposed to the labelled probe which 'hybridises', or attaches, to its complementary fragment of DNA. The length of this now-labelled fragment can be determined by its position on the filter.
As there is normally considerable variation in the base sequences of much of the human DNA, the division of one region of DNA by a single restriction enzyme may produce several fragments of different size. This variability produces a potentially huge number of 'polymorphic' markers suitable for linkage analysis. These normal variations in the size of DNA fragments are known as restriction fragment length polymorphisms (RFLPs).
Before linkage of a particular DNA region to a disorder can be tested, the frequency of the RFLPs in the normal population must be determined. For example, for a specific region of DNA there may normally be four RFLPs with frequences of, say, 0.3, 0.3, 0.1 and 0.3. The association between these RFLPs and a disorder is then examined in suitable family pedigrees by the use of complex statistical programs, such as LIPED.I9 If one of the RFLPs is found to be significantly more common in subjects with the disorder than it is in controls, it would strongly suggest that the responsible gene is located near that particular region of DNA.
The study of Egeland et aL4 involved families of the Old Order Amish community, a religious group of about 12,500 people living in Pennsylvania. This group was eminently suitable for genetic studies, as it is isolated, detailed family pedigrees are available and diagnosis of disorders is more accurate than usual because there are strict prohibitions on behaviours, such as alcohol abuse and antisocial activity, that might otherwise confound the definition of depression or mania. Perhaps more significantly, Egeland has demonstrated that the mode of inheritance in this community is due to a single autosomal dominant gene, with a penetrance of 63%.
One large pedigree of 81 members was investigated. Nineteen members of this family had major affective illness, mostly bipolar disorder. Tight linkage (a lod score > 3) was demonstrated to the c-Harvey-ras-1 oncogene (HRAS l), which is located at the tip of the short arm of chromosome 11. There was also a trend suggesting linkage, albeit looser, to the insulin gene (INS), which is situated nearby on chromosome 1 1. This indicated localisation of the gene responsible for bipolar disorder in the vicinity of HRAS 1 and INS, but closer to the former.
As has been the case with many important discoveries in medicine, this demonstration of linkage was an example of serendipity. There was no a priori rationale to investigate chromosome 11, which was in fact being studied for other medical disorders, but it certainly saved many years of fruitless research. When a disorder has no known specific biochemical abnormality, as is the case for bipolar illness, it is not possible to test for linkage to a specific gene. In such conditions, the search for linkage is akin to looking for the proverbial 'needle in a haystack'. Now that a particular region of chromosome 1 1 has been implicated, however, the theoretically intriguing issue is the possible involvement of the tyrosine hydroxylase gene (TH), which is located nearby. Tyrosine hydroxylase is the ratelimiting enzyme in the catecholamine biosynthetic pathway and its involvement would suggest the possibility of an abnormality in the regulation of TH or other associated proteins.
Egeland's discovery has been received enthusiastically in both the scientific2' and popular press. However, two negative findings published in a recent issue of Nature call for The second study to localise a dominant gene, that of Mendlewicz,' from Belgium, was based on 10 pedigrees with bipolar illness selected because of apparent X-linkage. Assuming a penetrance of 1 OO%, linkage was demonstrated to the gene for coagulation factor IX, which is located in the sub-terminal region of the long arm of the X-chromosome. Chromosome 1 1 was not investigated by this group.
Is it possible to reconcile these apparently divergent findings? Diagnostic issues cannot be implicated, as each group used formalised assessment procedures with RDC criteria derived from SADS-L interviews. There are two possible explanations. First, with regard to the chromosome 1 1 studies, significant linkage is more easily demonstrated in one very large pedigree, such as Egeland's, than in multiple smaller pedigrees, such as were used in the other two studies. The second, and perhaps more parsimonious, explanation is that bipolar disorder is genetically heterogeneous. It may be, for example, that susceptibility to bipolar disorder is the result of deficiency in the endproduct of a biochemical pathway, and that a number of enzyme deficits may lead to the same functional state. The genes for the different enzymes would not then necessarily be proximal to each other on the genome but would be distributed widely in areas including chromosome 1 1 and the X-chromosome.
What of the other functional psychoses? Studies in schizophrenic patients using, for example, neuropeptide probes, have already c~m m e n c e d .~~ Research progress in that disorder, however, is expected to be slower than that for bipolar disorder. Large pedigrees with high densities of illness are uncommon, and the inheritance probably is either due to a recessive major locus, or it is polygenic.
Despite these difficulties, the application of the techniques of molecular biology has significant potential for increasing our understanding of the cause of the functional p s y c h o~e s .~~-~ If findings can be replicated in different pedigrees (as has now been demonstrated in Huntington's chorea), further refinements of this procedure may provide useful diagnostic markers. Of greater significance is the potential for defining biochemical lesions once the abnormal genes have been localised (e.g., by the process of 'walking the chromosome') and the products characterised. The door would then be opened for specific treatments.
In the midst of the scientific ferment that is already being generated by these findings, the potential ethical problems will also need to be addressed. These issues are even now being faced by families with Huntington's chorea.26 The appropriateness of testing subjects at risk for the psychoses is a matter of particular concern as these illnesses have high suicide rates. With the recent advent of chorion villus sampling, it may even become possible to predict prenatally the risk of later development of these disorders.27
